|
Parameter
|
HeFH (n = 10)
|
HoFH (n = 4)
|
|---|
|
Lipids, mmol/l
|
Before LA
|
After LA
|
Decrease, n (%) patients
|
Before LA
|
After LA
|
Decrease, n (%) patients
|
|---|
|
TC
|
5.69 (1.16)
|
1.93 (0.59)***
|
10 (100)
|
7.09 (2.15)
|
1.95 (0.66)***
|
4 (100)
|
|
LDLC
|
3.57 (1.19)
|
0.75 (0.54)***
|
10 (100)
|
5.13 (1.87)
|
0.85 (0.94)***
|
4 (100)
|
|
HDLC
|
1.34 (0.65)
|
0.91 (0.33)***
|
10 (100)
|
1.51 (0.72)
|
1.15 (0.39)***
|
4 (100)
|
|
ApoB
|
1.11 (0.28)
|
0.28 (0.22)***
|
10 (100)
|
1.22 (0.50)
|
0.18 (0.17)***
|
4 (100)
|
|
Endoglin, ng/mL
|
6.45 (1.85)
|
5.56 (1.75)***
|
8 (80)
|
6.22 (1.73)
|
4.85 (1.80)***
|
3 (75)
|
|
CD40L, pg/mL
|
5323 (2059)
|
5367 (3093)
|
4 (40)
|
5177 (1585)
|
4239 (1892)
|
2 (50)
|
|
hsCRP, mg/L
|
2.84 (1.51)
|
2.39 (1.38)
|
6 (60)
|
2.21 (1.36)
|
1.82 (1.27)
|
3 (75)
|
|
MCP-1, pg/mL
|
321.8 (99.2)
|
274.5 (86.1)
|
6 (60)
|
265.6 (71.0)
|
221.4 (68.2)
|
3 (75)
|
|
sP-selectin, ng/mL
|
148.1 (50.7)
|
131.7 (53.8)*
|
7 (70)
|
145.6 (70.6)
|
154.3 (212.2)
|
3 (75)
|
- Data shows the level of parameters before and after each procedure during the time patients underwent LA and the percentage of cases (patients) where change was significant
- *p < 0.05, ***p < 0.001
